Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer

Daily Regimen ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Investigational New Drugs ◽

10.1007/s10637-018-0599-4 ◽

2018 ◽

Vol 36 (4) ◽

pp. 674-682 ◽

Cited By ~ 1

Author(s):

Arthur Lui ◽

Karen Mulder ◽

Christine Brezden-Masley ◽

Michael Vickers ◽

Jose Monzon ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Abstract A75: The IMPaCT trial: Individualised Molecular Pancreatic Cancer Therapy. A pilot, randomized, open label Phase II trial assessing first line treatment with gemcitabine or personalized treatment based on tumour molecular signature in patients with metastatic pancreatic cancer.

10.1158/1535-7163.targ-13-a75 ◽

2013 ◽

Author(s):

Lorraine Chantrill ◽

Amber Johns ◽

Adnan Nagrial ◽

Venessa Chin ◽

Angela Chou ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii Trial ◽

Molecular Signature ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Pancreatic Cancer Therapy ◽

The Impact ◽

Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-008-0873-9 ◽

2008 ◽

Vol 64 (2) ◽

pp. 317-325 ◽

Cited By ~ 11

Author(s):

Kyung Hee Lee ◽

Min Kyoung Kim ◽

Yeol Hong Kim ◽

Baek Yeol Ryoo ◽

Ho Yeong Lim ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Gemcitabine and oxaliplatin combination as the first-line treatment in advanced pancreatic cancer: A multicenter phase II study

10.1200/jco.2008.26.15_suppl.15618 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 15618-15618

Author(s):

K. Lee ◽

M. Kim ◽

Y. Kim ◽

B. Ryoo ◽

H. Lim ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

A multicentre, open-label phase II study of irinotecan, capecitabine, and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

10.1200/jco.2016.34.15_suppl.4032 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4032-4032

Author(s):

Arthur Gregory Ang Lui ◽

Karen E. Mulder ◽

Christine Brezden-Masley ◽

Michael M. Vickers ◽

Jose Gerard Monzon ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

Annals of Oncology ◽

10.1093/annonc/mdq247 ◽

2010 ◽

Vol 21 (11) ◽

pp. 2213-2219 ◽

Cited By ~ 80

Author(s):

S. Rao ◽

N. Starling ◽

D. Cunningham ◽

K. Sumpter ◽

D. Gilligan ◽

...

Keyword(s):

Gastric Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

PD07-07: Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a Randomized, Multicenter, Open-Label, Phase II Study of the Dutch Breast Cancer Trialists' Group (BOOG).

10.1158/0008-5472.sabcs11-pd07-07 ◽

2011 ◽

Author(s):

SW Lam ◽

SM de Groot ◽

AH Honkoop ◽

A Jager ◽

AJ ten Tije ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Results ◽

Locally Recurrent ◽

Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: an open-label, multicenter phase II study

10.1200/jco.2005.23.16_suppl.4141 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 4141-4141 ◽

Cited By ~ 1

Author(s):

H.-S. Song ◽

Y.-R. Do ◽

H.-M. Chang ◽

K.-H. Lee ◽

Y.-H. Kim ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Metastatic Pancreatic Cancer ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Multicenter Phase ◽

Interim safety analysis of a randomized phase II trial comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with advanced pancreatic cancer

10.1200/jco.2015.33.15_suppl.e15267 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e15267-e15267

Author(s):

Hiroaki Yanagimoto ◽

Takuji Okusaka ◽

Hiroshi Ishii ◽

Junji Furuse ◽

Shinichi Ohkawa ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Oral Therapy ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Standard Regimen ◽

Randomized Phase Ii ◽

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method

European Journal of Cancer ◽

10.1016/j.ejca.2020.12.029 ◽

2021 ◽

Vol 146 ◽

pp. 95-106

Author(s):

M. Haas ◽

D.T. Waldschmidt ◽

M. Stahl ◽

A. Reinacher-Schick ◽

J. Freiberg-Richter ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Metastatic Pancreatic Cancer ◽

Integrated Analysis ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽